Drug treatment for melanoma: progress, but who pays?
Richard F
RF
Kefford
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001315:Australia; D016527:Drug Costs; D005380:Financing, Government; D006291:Health Policy / Q000191:economics*; D006801:Humans; D007211:Indoles / Q000191:economics / Q000627:therapeutic use*; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000191:economics; D009313:National Health Programs / Q000191:economics; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use*; D000077484:Vemurafenib
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007211:Indoles; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib